JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v1i1.114Review ArticleCritical Path to Tuberculosis Drug Regimens: Global  collaboration to accelerate development of novel  drug regimens and rapid drug susceptibility tests for  tuberculosishttps://artdesignp.com/journal/JMDS/1/1/10.18063/jmds.v1i1.114HannaDebra,SchitoMarco,RomeroKlaus2015112015-07-07The Critical Path to Tuberculosis Drug Regimens (CPTR) initiative aims to support the rational deployment of new tuberculosis (TB) therapies by speeding the development and impact of new and markedly improved drug regimens as well as rapid drug susceptibility tests. Co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance in 2010, CPTR is a coalition comprising the world’s leading pharmaceutical companies, product development sponsors, diagnostic companies, regulatory agencies, and civil society organizations which support and catalyze advances in regulatory science, the development of infrastructure, and other progress needed to accelerate the pace of development and introduction of novel regimens and rapid drug susceptibility tests. This manuscript summarizes the work of two subgroups within CPTR, the Regulatory Sciences and Rapid Drug Susceptibility Test consortia, and their efforts to drive innovation. These consortia are supported by a robust TB clinical data platform, which continues to evolve through contributions of contemporary TB clinical trial data sets as well as whole genome sequence level data from isolates across the globe. Examples of innovation are described and include a recently-qualified drug development tool and emerging programs to support the development of clinical trial simulation tools.tuberculosis, TB drug regimens, TB diagnostics, clinical trial simulation tools, consortium

1. WHO Global Tuberculosis Report 2014, viewed April 9, 2015, <http://www.who.int/tb/publications/global_report/en/>2. Critical Path to Tuberculosis Drug Regimens, n.d., viewed April 9, 2015, <http://c-path.org/programs/cptr/>3. Tuberculosis Therapeutic Area User Guide v1, 2012, viewed April 9, 2015, <http://cdisc.org/therapeutic#tuberculosis>4. Qualification opinion: In-vitro hollow fiber system model of tuberculosis (HSF-TB), 2015, viewed April 9, 2015, <http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/02/WC500181899.pdf>5. Jamei M, Marciniak S, Edwards D, et al. 2013, The Simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacology, vol.1(1): 1–14. http://dx.doi.org/10.1186/2193-9616-1-9.6. Egelund E F, Weiner M, Singh R P, et al. 2014, Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy, vol.58(8): 4904–4910. http://dx.doi.org/10.1128/AAC.01730-13.7. Peloquin C A, Jaresko G S, Yong C L, et al. 1997, Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrobial Agents and Chemotherapy, vol.41(12): 2670–2679.8. Zhu M, Starke J R, Burman WJ, et al. 2002, Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy, vol.22(6): 686–695. http://dx.doi.org/10.1592/phco.22.9.686.34067.9. Parida S K and Kaufmann S H, 2010, The quest for biomarkers in tuberculosis. Drug Discovery Today, vol.15(3–4): 148–157. http://dx.doi.org/10.1016/j.drudis.2009.10.005.10. Wallis R S, Doherty T M, Onyebujoh P, et al. 2009, Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet Infectious Diseases, vol.9(3): 162–172. http://dx.doi.org/10.1016/S1473-3099(09)70042-8.11. Epstein M D, Schluger N W, Davidow A L, et al. 1998, Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest, vol.113(2): 379–386. http://dx.doi.org/10.1378/chest.113.2.379.12. Marino S and Kirschner D, 2004, The human immune response to Mycobacterium tuberculosis in lung and lymph node. Journal of Theoretical Biology, vol.227(4): 463–486. http://dx.doi.org/10.1016/j.jtbi.2003.11.023.13. Darpo B, Benson C, Dota C, et al. 2015, Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clinical Pharmacology and Therapeutics, vol.97(4): 326–335. http://dx.doi.org/10.1002/cpt.60.14. Johannesen L, Vicente J, Gray R A, et al. 2014, Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clinical Pharmacology and Therapeutics, vol.95(5): 501–508. http://dx.doi.org/10.1038/clpt.2013.238.